Why Valeant Pharmaceuticals' Rebound Fizzled

For a few weeks in January Valeant Pharmaceuticals NYSE VRX stock outperformed the S amp P 500 index The run didn t last long though Here s why Valeant s rebound quickly fizzled Anatomy of a letdown The first phase of Valeant s failed rebound started with the stock